The sector’s XBI is up 15% year-to-date; rate cuts, election outcome, and M&A are viewed as tailwinds.
Biotech Investor Sentiment Climbing Steadily, with Growing Enthusiasm Heading into 2025
Posted on by admin
1 min read
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025

+ There are no comments
Add yours